XML 44 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Balance Sheet Components - Additional Information (Detail)
3 Months Ended
Mar. 31, 2020
USD ($)
Milestone
Dec. 31, 2019
USD ($)
Schedule of Available-for-sale Securities [Line Items]    
Cash and cash equivalents $ 121,560,000 $ 126,266,000
Contractual maturities of available-for-sale investments 1 year  
Other-than-temporary impairment loss $ 0  
Number of regulatory milestones | Milestone 2  
Unbilled contract assets $ 130,000,000 180,000,000
Active pharmaceutical ingredient product price change in estimated variable consideration 0 36,324,000
Accrued long-term co-promotional expenses 78,301,000 53,071,000
Accounts Receivable [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Billed contract assets 50,000,000.0  
Europe [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unbilled contract assets 130,000,000.0  
Astellas Agreement [Member] | Europe [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unbilled contract assets 130,000,000.0  
AstraZeneca Agreements [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unbilled contract assets 50,000,000.0  
Accrued long-term co-promotional expenses 78,300,000 53,100,000
AstraZeneca Agreements [Member] | U.S./RoW [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unbilled contract assets   50,000,000.0
Foreign subsidiaries [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Cash and cash equivalents $ 29,800,000 $ 11,900,000